Inventiva is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH). Its lead product candidate, lanifibranor, is an oral PPAR agonist currently undergoing a global Phase III clinical trial to evaluate its efficacy in treating MASH with fibrosis stages F2 and F3. The company holds global development and commercialization rights for lanifibranor, excluding Greater China, Japan, and South Korea, where it has entered licensing agreements with Sino Biopharmaceutical and Hepalys Pharma, respectively. Inventiva was created in 2012 following the divestiture of the research unit by Abbott Laboratories, which had acquired the asset from Fournier. The company's pipeline targets metabolic dysfunction, inflammation, and fibrosis in metabolic liver disease.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage inventivapharma.com
Sector Healthcare IR page inventivapharma.com/investors
Tags
metabolic dysfunction-associated steatohepatitis, oral small molecules, ppar agonists, liver disease, clinical-stage, cardiometabolic health, fibrosis, inflammation, type 2 diabetes, lanifibranor, NATiV3, NATIVE, LEGEND, Sino Biopharmaceutical, Hepalys Pharma, Abbott Laboratories, Fournier
Press page —

Metrics

Valuation  
Market cap € 636.658M
Market cap (USD) $ 699.623M
P/E -1.73
PEG —
P/BV 10.79
P/S 142.02
P/OCF -6.07
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 1,241.6%
ROI —
ROIC —
Profit margin -7,899.6%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) —
Debt/Equity 113.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -61.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 4.483M 9.198M 17.477M 12.179M 4.194M 372K 6.998M
Net profit -354.138M -184.212M -110.426M -54.274M -49.635M -33.619M -30.218M
Free cash flow -105.131M -86.261M -82.154M -45.489M -48.163M -30.882M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 3.96 1.95 4.15 4.43 11.59 12.4 —
Price performance 12m 1.17 -0.53 0.01 -0.67 -0.06 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Income detail
Research and development expense (EUR) 31.8M 33.8M 23.7M 48.5M 60.5M 110M 90.9M 87M
↳ 5y CAGR +28.2% +21.9% +29.7%
Reported Mar 15, 2021 Mar 15, 2021 Mar 15, 2021 Mar 11, 2022 Mar 30, 2023 Apr 3, 2024 Apr 15, 2025 Apr 8, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Franchissements de seuil Bull 0 Bear 0 Routine
Franchissements de seuil Bull 0 Bear 0 Routine
Franchissement de seuil Bull 0 Bear 0 Routine

Prompts

Inventiva S.A. (ticker IVA), listed in France.

ETFs Holding Inventiva S.A.

ETF Weight in ETF Shares Market value As of
SURI 1.47% 311,468 $ 1.003M Nov 17, 2026
MEDI 0.30% 32,662 $ 126.729K Nov 12, 2026
APIE 0.00% 10,081 $ 47.179K Aug 31, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
IVA Common share — US nasdaq 3.69 USD 2026-09-30
IVA canonical Common share — FR euronext 3.29 EUR 2025-11-21